Objective: To describe correlations of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part III scores with the 39-item Parkinson’s disease (PD) questionnaire (PDQ-39) total and activities of daily living (ADLs) domain scores, and MDS-UPDRS part II scores, in CTH-300 participants.

Background: Long-term treatment of PD with levodopa is associated with “OFF” episodes that adversely impact patients’ quality of life (QoL). The PDQ-39, and the MDS-UPDRS were administered in a phase 3, randomized, placebo-controlled trial that demonstrated the efficacy and tolerability of apomorphine sublingual film (APL-130277) for the acute treatment of OFF episodes in levodopa-responsive patients with PD (CTH-300; NCT02469090). MDS-UPDRS part III scores were used to evaluate efficacy, and their correlation with HRQoL and ADLs is of value.

Method: At screening visit 2 (SV2) and maintenance visit 4 (MV4) (92-135 days from SV2), patients completed the PDQ-39 (high score=poorer QoL) and MDS-UPDRS part II (motor experiences of daily living; high score=greater impairment); a clinician completed the MDS-UPDRS part III (motor impairment; high score=greater impairment). Mean PDQ-39 and MDS-UPDRS scores, and Pearson correlation coefficients were evaluated.

Results: A total of 108 patients completed both scales at SV2, of which 80 contributed data at MV4. The mean (SD) age of the population was 62.7 (8.95) years, majority were male (62.4%), and White (92.7%). Mean (SD) time since diagnosis of PD = 9.0 (4.0) years, and mean (SD) time since motor fluctuations started = 4.6 (3.8) years. Mean (SD) PDQ-39 total score was 26.4 (15.0) and 24.1 (14.3) at SV2 and MV4, respectively. Mean scores for the 8 PDQ-39 domains ranged from 8.0 (social support) to 42.0 (bodily discomfort). Mean (SD) MDS-UPDRS part III score was 43.3 (13.8) and 40.1 (13.9) at SV2 and MV4, respectively. MDS-UPDRS part III scores showed significant correlation with PDQ-39 total scores, the PDQ-39 ADLs domain, and MDS-UPDRS part II scores at SV2 (Table 1). The results were consistent at MV4 (Table 2).

Conclusion: MDS-UPDRS part III correlated well with PDQ-39 total. Further, part III correlated well with the concept of ADLs, as measured by PDQ-39 ADLs domain or MDS-UPDRS part II. These results suggest that motor function, as measured by MDS-UPDRS part III, is correlated with HRQoL and ADLs.

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/correlation-between-pdq-39-and-mds-updrs-scores-in-a-phase-3-randomized-controlled-trial-of-patients-with-parkinsons-disease/